Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 5/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21600737 | 0.85 | PSEN1 (0.40) | MMP2MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL21600709 | 0.84 | PSIP1 (0.36) | ALDH1A1HTR2A | |
| SCHEMBL21600738 | 0.83 | ALDH1A1 (0.39) | ALDH1A1GRM2HTR6NFE2L2 | |
| SCHEMBL29457729 | 0.81 | TSHR (0.51) | ALDH1A1 | |
| SCHEMBL21600726 | 0.81 | TSHR (0.51) | ALDH1A1 | |
| SCHEMBL21600743 | 0.78 | CYP3A4 (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL30662156 | 0.78 | CYP3A4 (0.37) | MEN1KMT2AALDH1A1 | |
| SCHEMBL21600727 | 0.78 | NAPRT (0.37) | MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL29457722 | 0.78 | NAPRT (0.37) | MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL23142584 | 0.78 | MCOLN3 (0.35) | ALDH1A1HTR2AHTR2CKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | FUJIAN HAIXI PHARMACEUTICALS CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | FUJIAN HAIXI PHARMACEUTICALS CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| EP-3798211-A1 | COMPOUND AND USE THEREOF IN SYNTHESIS OF BRIVARACETAM INTERMEDIATE AND CRUDE DRUG | Fujian Haixi Pharmaceuticals Co., Ltd (CN) | 2021-03-31 | — | — | EP | disclosed |
| WO-2019242692-A1 | COMPOUND AND USE THEREOF IN SYNTHESIS OF BRIVARACETAM INTERMEDIATE AND CRUDE DRUG | 福建海西新药创制有限公司 | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247977-B2 | Compound and use thereof in synthesis of brivaracetam intermediate and crude drug | CYP3A43, POR, CYP2C19 | MMP2 2377/4885MEN1 4199/4885KMT2A 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.